Disclosure Decoder #011: Samsung Biologics' smaller rights offering leaves KRW 336bn of spending to its own funds
Samsung Biologics' first-round price of KRW 1.174mn (~$862) cuts indicated proceeds to KRW 2,665bn (~$1,956M). Under its stated priority order, the whole raise now goes to the securities acquisition and the KRW 295bn (~$216M) facility line drops out.
The Filing
Samsung Biologics (DART 00877059) filed an amended material-event report on 1 October 2026, correcting its original 28 August 2026 rights offering decision report. The amendment reflects the setting of the first-round indicative issue price and updates the reference to the prospectus filing date.
What It Literally Says
The amendment makes two substantive changes. First, the fund-use table is revised: the facility-investment line of KRW 295bn (~$216M) is removed, and the acquisition-of-securities-in-other-companies line moves from KRW 2,706bn (~$1,986M) to KRW 2,665bn (~$1,956M), cutting the total stated use from KRW 3,001bn (~$2,203M) to KRW 2,665bn (~$1,956M). Second, the first-round indicative price for common shares is set at KRW 1.174mn (~$862) per share, down from the earlier indicative figure of KRW 1.322mn (~$970). The final price determination date remains 4 November 2026. All other terms of the offering are unchanged: 2,270,000 new common shares, par value KRW 2,500 (~$1.84), rights-offering with public offer of unsubscribed shares, record date 6 October 2026, subscription dates 9 to 10 November 2026 for existing shareholders and 12 to 13 November 2026 for the public, payment date 17 November 2026, and listing of new shares on 30 November 2026.
The single most revealing detail in this filing, and KoreaAlpha's conviction read, are available to Premium subscribers.
